The Scottish Medicines Consortium (SMC) has approved the use of daratumumab (Darzalex) to treat myeloma patients on National Health Service (NHS) Scotland.
The UK National Institute for Health and Care Excellence (NICE) has issued a second draft ‘no’ on Takeda’s Ninlaro (ixazomib) for the treatment of patients with relapsed or refractory myeloma.